SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Carbylan Therapeutics, Inc. (CBYL)

NEW YORK, March 22, 2016

This investigation concerns whether Carbylan and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

Carbylan Therapeutics is a pharmaceutical company that develops and commercializes novel, chemically engineered polymer systems and proprietary combination therapies.

On April 9, 2015, Carbylan held its Initial Public Offering, selling 13 million shares of its stock. The Company raised $65 million in new capital. On February 1, 2016, Carbylan revealed its top-line results from COR1.1, its first Phase 3 trial of Hydros-TA for the treatment of knee pain associated with osteoarthritis. Following this news, Carbylan stock dropped, and has fallen by 92.8% from its high of $9.22 per share on June 8, 2015, to close at $0.66 per share on March 17, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Carbylan, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!cbyl/vcdhz.  You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com